Validation of PRKD1 p.Glu710Asomatictic mutation status in PLGAs from the validation series by Sanger sequencing.
Here we describe an assay for the identification of the expressed VH segment and its mutation status in CLL.
Defining the BRAF mutation status in metastatic melanoma patients is critical to selecting patients for therapeutic treatment with targeted therapies.
To further confirm a role of KRAS mutation status in PTPRS KO-mediated modulation of EGFR phosphorylation response, we used isogenic cell pairs HCT116 (KRAS G13D/+) vs HCT116 with and without PTPRS expression.
Jo P, König A, Schirmer M, Kitz J, Conradi LC, Azizian A, Bernhardt M, Wolff HA, Grade M, Ghadimi M, Ströbel P, Schildhaus HU, Gaedcke J. Heterogeneity of KRAS Mutation Status in Rectal Cancer.
Immunohistochemical analysis using an antibody specific to nuclear NOTCH1 correlates with mutation status in sporadic cSCC and regions of NOTCH1 loss or down-regulation are frequently observed in normal looking skin.
Comparison of this recent PSAAP algorithm with established on-line prediction tools may improve our understanding of predicting mutation status in the RET proto-oncogene.
In a previous study [26], however, we analyzed for CHEK2 mutation status in relation to therapy outcome in a cohort of patients from doxorubicin study [13].
First, we could not compare the results of the EGFR mutation status in the pleural effusion fluid to the mutation status in tumour tissue.
In addition, we compared the mutation status in plasma to the mutation status in the original diagnosis biopsy from the same patients.
Genotyping of BRAF mutation status in melanoma patients was performed as previously described.
